Tumor Mutational Burden Predicts Progression-Free Survival and Local-Regional Control in Locally Advanced Non-Small Cell Lung Cancer Patients Treated with Chemoradiation and Durvalumab

被引：0
|
作者：
Shaverdian, N. [1 ]
Shepherd, A. F. [1 ]
Offin, M. [2 ]
Gelblum, D. [1 ]
Wu, A. J. [1 ]
Simone, C. B., II [3 ]
Schoenfeld, A. J. [2 ]
Jones, D. [4 ]
Rimner, A. [1 ]
Chaft, J. [4 ]
Riaz, N. [1 ]
Gomez, D. R. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY USA
[3] New York Proton Ctr, New York, NY USA
[4] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2022年 / 114卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2873
引用
收藏
页码：E390 / E391
页数：2
相关论文
共 50 条
  • [21] Safety and efficacy of durvalumab after concurrent chemoradiation in Black patients with locally advanced non-small cell lung cancer
    McCall, Neal S.
    Janopaul-Naylor, James R.
    McGinnis, H. Scott
    Kesarwala, Aparna H.
    Tian, Sibo
    Stokes, William A.
    Shelton, Joseph W.
    Steuer, Conor E.
    Carlisle, Jennifer W.
    Leal, Ticiana A.
    Ramalingam, Suresh S.
    Bradley, Jeffrey D.
    Higgins, Kristin A.
    CANCER, 2023, 129 (23) : 3713 - 3723
  • [22] PET Metabolic Tumor Response by PERCIST Reliably Predicts Local Regional Control in Locally Advanced Non-Small Cell Lung Cancer After Concurrent Chemoradiation Therapy With Erlotinib
    Wei, X.
    Allen, P. K.
    Erasmus, J.
    Blumenschein, G. R.
    Godoy, M.
    Lee, J. J.
    O'Reilly, M. S.
    Welsh, J. W.
    Cox, J. D.
    Hong, W. K.
    Komaki, R. U.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E402 - E403
  • [23] Immune Parameters as Predictors of Pneumonitis and Survival in Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation
    Ho, Quoc-Anh
    Qi, Lihong
    Rao, Shyam S.
    Daly, Megan E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (02): : E36 - E37
  • [24] Initial serum tumor marker change predicts progression-free and overall survival in immune checkpoint blockade treated non-small cell lung cancer
    Lang, David
    Horner, Andreas
    Brehm, Elmar
    Romain, Silas
    Kaiser, Bernhard
    Lamprecht, Bernd
    WIENER KLINISCHE WOCHENSCHRIFT, 2018, 130 (19-20) : 618 - 619
  • [25] Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer
    Komaki, Ritsuko
    Allen, Pamela K.
    Wei, Xiong
    Blumenschein, George R.
    Tang, Ximing
    Lee, J. Jack
    Welsh, James W.
    Wistuba, Ignacio I.
    Liu, Diane D.
    Hong, Waun Ki
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 92 (02): : 317 - 324
  • [26] Tumor Mutational Burden in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy: Outcomes in a Multiethnic Cohort
    Munoz-Arcos, L.
    D'Aiello, A.
    Herbert, J.
    Cheng, H.
    Halmos, B.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S408 - S409
  • [27] Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy
    Akamatsu, Hiroaki
    Mori, Keita
    Naito, Tateaki
    Imai, Hisao
    Ono, Akira
    Shukuya, Takehito
    Taira, Tetsuhiko
    Kenmotsu, Hirotsugu
    Murakami, Haruyasu
    Endo, Masahiro
    Harada, Hideyuki
    Takahashi, Toshiaki
    Yamamoto, Nobuyuki
    BMC CANCER, 2014, 14
  • [28] Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy
    Hiroaki Akamatsu
    Keita Mori
    Tateaki Naito
    Hisao Imai
    Akira Ono
    Takehito Shukuya
    Tetsuhiko Taira
    Hirotsugu Kenmotsu
    Haruyasu Murakami
    Masahiro Endo
    Hideyuki Harada
    Toshiaki Takahashi
    Nobuyuki Yamamoto
    BMC Cancer, 14
  • [29] Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy
    Hendriks, Lizza E.
    Rouleau, Etienne
    Besse, Benjamin
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 (06) : 647 - 660
  • [30] Concomitant chemoradiation for locally advanced non-small cell lung cancer
    Hennequin, C.
    Mornex, F.
    Tredaniel, J.
    ONCOLOGIE, 2008, 10 (09) : 531 - 535
12345